ANTX AN2 Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1880438 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.5%
TTM EPS YoY19.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-51.3%
ROA-46.7%
ROIC (approx.)-60.6%
Asset turnover—
Leverage & solvency
Liabilities / assets7.9%
Debt / equity0.00x
Current ratio10.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $24.77M | $40.49M | $54.87M | $28.51M | $16.16M |
| SG&A expense | $13.34M | $14.07M | $14.76M | $12.75M | $4.67M |
| Operating income | -$38.11M | -$56.79M | -$69.64M | -$42.26M | -$21.57M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$35.17M | -$51.32M | -$64.73M | -$40.96M | -$21.54M |
| EPS (basic) | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 |
| EPS (diluted) | -1.16 | -1.72 | -2.74 | -2.79 | -10.64 |
| Weighted avg. shares (diluted) | 30.22M | 29.83M | 23.60M | 15.34M | 2.64M |
| Balance sheet | |||||
| Cash & equivalents | $19.94M | $21.35M | $15.65M | $27.22M | $12.10M |
| Short-term investments | $38.06M | $62.27M | $91.65M | $68.84M | $46.46M |
| Current assets | $59.94M | $86.26M | $110.51M | $98.62M | $60.11M |
| Total assets | $61.95M | $92.09M | $138.74M | $102.56M | $65.32M |
| Current liabilities | $8.72M | $10.24M | $14.04M | $7.19M | $3.40M |
| Total liabilities | $8.89M | $10.24M | $14.04M | $7.19M | $3.41M |
| Shareholders' equity | $53.06M | $81.85M | $124.70M | $95.37M | -$47.41M |
| Shares outstanding | 27.41M | 29.92M | 29.74M | 19.40M | 2.73M |
| Cash flow statement | |||||
| Operating cash flow | -$29.83M | -$49.26M | -$53.29M | -$33.46M | -$20.48M |
| Investing cash flow | $28.31M | $54.59M | -$43.28M | -$21.77M | -$50.02M |
| Financing cash flow | $113,000 | $372,000 | $84.99M | $70.36M | $78.53M |
| Stock-based compensation | $6.25M | $8.34M | $8.41M | $4.39M | $974,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.